{
    "clinical_study": {
        "@rank": "73830", 
        "arm_group": [
            {
                "arm_group_label": "ZES group", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "EES group", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Vytorin group", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Mevalotin group", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Objective: To evaluate the early effects of intensive lipid lowering treatments with\n      ezetimibe/simvastatin (Vytorin\u00ae) for each component of coronary plaques.\n\n      Study Design\n\n        -  Prospective, randomized, single-center study of each 80 subjects enrolled\n\n        -  Subjects with acute coronary syndrome who meet all inclusion and exclusion criteria\n           will be enrolled.\n\n        -  Eligible subjects will be randomized 1:1 to A) Ezetimibe/Simvastatin (n=80) vs. B)\n           Pravastatin (n=80), and each group of patients will be randomized further in a ratio of\n           1:1 to a) ZES (n=40) vs. b) EES (n=40), according to the type of stent used.\n\n        -  All subjects will undergo VH-IVUS at initial procedure.\n\n        -  Follow-up VH-IVUS will be performed at 3 months after index procedure. OCT at initial\n           procedure and 3-months will be performed in available cases."
        }, 
        "brief_title": "Early Effects of Intensive Lipid Lowering Treatment With Ezetimibe/ Simvastatin (Vytorin\u00ae) Assessed by Virtual Histology-Intravascular Ultrasound (VH-IVUS) and Optical Coherence Tomography (OCT) on Plaque Characteristics in Patients With Acute Coronary Syndrome", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Acute Coronary Syndrome", 
        "condition_browse": {
            "mesh_term": "Acute Coronary Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        General inclusion criteria\n\n          1. Acute coronary syndrome including unstable angina, acute non-ST elevation myocardial\n             infarction and acute ST elevation myocardial infarction\n\n          2. Age of 20 years or older\n\n          3. Patients with signed informed consent\n\n        Angiographic inclusion criteria\n\n          1. De novo lesion without significant plaque (angiographic lumen diameter stenosis <\n             50%)\n\n          2. Reference vessel diameter ?> 3.0 mm by operator assessment\n\n          3. Segment length of 10-20 mm\n\n          4. Distance from the PCI site > 5.0mm (either proximal or distal)\n\n          5. Available for serial high quality IVUS studies of the entire segment.\n\n        Exclusion Criteria:\n\n          1. Failed PCI\n\n          2. Recommended coronary artery bypass grafting (CABG)\n\n          3. Cardiogenic Shock\n\n          4. Administration of lipid lowering agents before enrollment\n\n          5. Significant hepatic dysfunction (3 times normal reference values)\n\n          6. Significant renal dysfunction (Serum creatinine > 2.0 mg/dl)\n\n          7. Significant leukopenia, thrombocytopenia, anemia, or known bleeding diathesis\n\n          8. Pregnant women or women with potential childbearing\n\n          9. Saphenous vein graft"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01857843", 
            "org_study_id": "1-2009-0032"
        }, 
        "intervention": [
            {
                "arm_group_label": "ZES group", 
                "description": "Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.\nPatients with native coronary arteries who fulfill all enrollment criteria for OCT study will be randomized to receive either ZES (Endeavor\u00ae-Sprint or Resolute-integrity) or EES (Xience\u00ae) in a ratio of 1:1.", 
                "intervention_name": "Zotalolimus Eluting Stent", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "EES group", 
                "description": "Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.\nPatients with native coronary arteries who fulfill all enrollment criteria for OCT study will be randomized to receive either ZES (Endeavor\u00ae-Sprint or resolute-integrity) or EES (Xience\u00ae) in a ratio of 1:1.", 
                "intervention_name": "Everolimus eluting stent", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Vytorin group", 
                "description": "Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.\nPatients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.\nEzetimibe 10mg/Simvastatin 40mg (Vytorin\u00ae, MSD)\nPravastatin 20mg (mevalotin\u00ae, BMS)", 
                "intervention_name": "Ezetimibe 10mg & Simvastatin 40mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Mevalotin group", 
                "description": "Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.\nPatients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.\nEzetimibe 10mg/Simvastatin 40mg (Vytorin\u00ae, MSD)\nPravastatin 20mg (mevalotin\u00ae, BMS)", 
                "intervention_name": "Pravastatin 20mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Everolimus", 
                "Simvastatin", 
                "Pravastatin", 
                "Ezetimibe"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "120-752"
                }, 
                "name": "Severance Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Quantitative change in fibrofatty component of plaque measured by VH-IVUS", 
            "safety_issue": "No", 
            "time_frame": "baseline and 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01857843"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Yonsei University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yonsei University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}